Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results

The T cell receptor fusion construct (TRuC) gavocabtagene autoleucel (gavo-cel) consists of single-domain anti-mesothelin antibody that integrates into the endogenous T cell receptor (TCR) and engages the signaling capacity of the entire TCR upon mesothelin binding. Here we describe phase 1 results...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassan, Raffit, Butler, Marcus, O’Cearbhaill, Roisin E., Oh, David Y., Johnson, Melissa, Zikaras, Kevin, Smalley, Munisha, Ross, Michael, Tanyi, Janos L., Ghafoor, Azam, Shah, Nirali N., Saboury, Babak, Cao, Liang, Quintás-Cardama, Alfonso, Hong, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427427/
https://www.ncbi.nlm.nih.gov/pubmed/37501016
http://dx.doi.org/10.1038/s41591-023-02452-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427427/
https://www.ncbi.nlm.nih.gov/pubmed/37501016
http://dx.doi.org/10.1038/s41591-023-02452-y

Ejemplares similares